Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2018-05-16

Clinical Trial Update: Eplerenone for Central Serous Chorioretinopathy [Phase 2]

View source ↗

Summary

Tufts Medical Center completed a Phase 2 trial of eplerenone for Central Serous Chorioretinopathy and posted results in May 2018.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Inspra (eplerenone)

Snippet

Sponsor: Tufts Medical Center | Conditions: Central Serous Chorioretinopathy | Phase 2 | Status: COMPLETED | Results posted: 2018-05-16